Talapo Therapeutics

LA JOLLA, CA · Founded 2016 · Biotech · Private

protein-based therapeutic (TL) that inhibits TGF pathways to suppress fat cell formation and reduce adipose tissue

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Biotech
Headquarters
LA JOLLA, CA
Founded
2016
Latest Form D
$100K, Dec 2017
Total capital
$1.1M
Federal grants
$1M
4 awards · 2018
Rank in peer group#234 of 502
Private capital raised
$100K
1 Form D · last Dec 2017
107 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20172018FEDERAL ↑EQUITY ↓Cumulative $1.1M$225K$225K$290K$290K1st Form D$100K
20172018FEDERAL ↑EQUITY ↓Cumulative $1.1M$225K$225K$290K$290K1st Form D$100K

Latest events

  • Federal grantHealth and Human S · Phase I · Targeting TGF-beta growth factors to treat obesity$290K
  • Federal grantHealth and Human S · Phase I · Targeting TGF-beta growth factors to treat obesity$290K
  • Federal grantHealth and Human S · Phase I · Cerberus therapy for metastatic disease$225K
  • Federal grantHealth and Human S · Phase I · Cerberus therapy for metastatic disease$225K
  • Private capital raisedForm D · SEC · 1st filing$100K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 502 peers

Line = median

Biotech · Molecule

  • Federal grants#234 · top 47%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Davorka MessmerResearcherExecutive Officer, DirectorLinked by $515K in grants as PI
  • Craig HardingDirectorNamed in SEC Form D filings
  • Erik Martinez-HackertDirectorNamed in SEC Form D filings
  • Neil SenturiaExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • Nymirum, Inc.Similar federal contract value in Biotech · null in contracts
  • Covira SurgicalSimilar federal contract value in Biotech · null in contracts
  • CHEMOSEN3D INCSimilar federal contract value in Biotech · null in contracts
  • RAINBIO, INC.Similar federal contract value in Biotech · null in contracts
  • LACTIGA US INC.Similar federal contract value in Biotech · null in contracts
  • Topogen, IncSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .